Darovasertib
Small molecule
Evidence outlook · lead readout
DAR-UM-2 (NCT05987332) · Uveal Melanoma
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
DAR-UM-2 (NCT05987332): This was a randomized, open-label Phase 2/3 trial with 420 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-13. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.
Company guidance: regulatory filing expected H2 2026 (IDEAYA Biosciences, 4 Aug 2026). “Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03947385 NCT03947385 · Uveal Melanoma Registry: NCT03947385 | 1/2 | Dose-limiting Toxicity (DLT) (28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib); Incidence of Adverse Events (Approx. 8 months); Maximum Tolerated Dose (MTD) (28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib); Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with Crizotinib (Approx. 6 months); Plasma Concentrations of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib (Approx. 6 months); Plasma Concentrations of Crizotinib administered in combination with IDE196 (Approx. 6 months); Plasma Concentrations of Binimetinib administered in combination with IDE196 (Approx. 6 months); Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment (Approx. 8 months); Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment (Approx. 8 months) 2027-01-29 | In progress: results expected 29 Jan 2027 | not yet graded | link ↗ |
View 4 more trials
DAR-UM-2 NCT05987332 · Uveal Melanoma This was a randomized, open-label Phase 2/3 trial with 420 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-13. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate. Registry: NCT05987332 | 2/3 | Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: (Approximately 5 months); Phase 2 Progression-Free Survival (PFS) (Approximately 2 years); Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment. (Approximately 4 years) 2027-01-15 | Primary endpoint, PFS by blinded independent central review: median 6.9 vs 3.1 months vs investigator's choice (HR 0.42; 95% CI 0.30-0.59) (IDEAYA, 2026-04-13). | Partial signal | link ↗ |
NCT05907954 NCT05907954 · Uveal Melanoma Registry: NCT05907954 | 2 | Incidence of Adverse Events (AEs) and significant laboratory abnormalities (from first dose to 28 days after last dose of therapy, approximately 18 months); Cohort 1 (enucleation): Number of patients converted from requiring enucleation to radiation (from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months); Cohort 2 (plaque brachytherapy): Estimated change in modeled radiation dose (from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months); Cohort 3 (patients with small UM tumors): Number of patients with clinical benefit per protocol-defined UM response criteria (from first dose of neoadjuvant to end of neoadjuvant therapy, approximately 12 months) 2027-04-30 | In progress: results expected 30 Apr 2027 | not yet graded | link ↗ |
NCT07015190 NCT07015190 · Uveal Melanoma Registry: NCT07015190 | 3 | Cohort 1: To demonstrate that the proportion of subjects with vision loss is lower for subjects in the Treatment Arm vs the Control Arm (Approximately 3 years); Cohort 2: To demonstrate the ability to salvage the eye and prevent enucleation in the Treatment Arm (Approximately 2 years) 2030-10 | In progress: results expected 1 Oct 2030 | not yet graded | link ↗ |
NCT07804186 NCT07804186 · Uveal Melanoma Registry: NCT07804186 | 3 | Median relapse-free survival (Approximately 5 years) 2034-03 | In progress: results expected 1 Mar 2034 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Uveal Melanoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Darovasertib: this drug | Phase 3 | Small molecule | Protein kinase C (PKC) (inhibitor) | Partial signal | NCT05987332: Primary endpoint, PFS by blinded independent central review: median 6.9 vs 3.1 months vs investigator's choice (HR 0.42; 95% CI 0.30-0.59) (IDEAYA, 2026-04-13). | |
| Tebentafusp-Tebn (KIMMTRAK) | Approved | Protein / enzyme therapeutic | gp100-HLA-A*02:01 x CD3 | Partial signal | NCT03070392: Efficacy: Overall Survival (From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.): Tebentafusp 21.7 Months (95% CI 18.6 to 28.6) | Investigator's Choice 16 Months (95% CI 9.7 to 18.4) | |
| Sturlimogene Erparepvec | Phase 2/3 | Oncolytic virus | Oncolytic HSV-1 (tumour lysis and immune stimulation) | not yet graded | No reviewed efficacy summary in this indication | |
| Roginolisib | Phase 2 | Small molecule | PI3K-delta | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Darovasertib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
January 2027 (2)
April 2027 (1)
What to watch
2030 (1)
October 2030 (1)
What to watch
2034 (1)
March 2034 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent